López-Alvarenga JC, Vargas JA, Schneider-Ehrenberg OP, Comuzzie AG, González J, Martínez JL

Language: Spanish
References: 46
Page: 109-114
PDF size: 72.90 Kb.

ABSTRACT

Objective: The etiology, comorbidity, metabolism, and treatment response vary among overweight and obesity types I, II and III individuals. We assessed the association between obesity type with body mass index, waist circumference and tolerance to a daily dose of 15 mg of sibutramine.
Materials and methods: A sample of 701 individuals recruited from 47 health centers was analyzed. All subjects received 15 mg of sibutramine daily for 8 weeks. Weight, height, and waist circumference were measured at day 0 and weeks 4 and 8.
Results: Patients in all obesity types lost proportional amounts of weight (p=0.86), but those in type III obesity had a smaller reduction in waist circumference than those in types I and II (p=0.003). Side effects of sibutramine were rarely observed. Subjects with type III obesity exhibited even fewer side effects.
Conclusions: The lack of association between weight reduction and decreased waist circumference across obesity types could be related to differences in the sympathetic nervous system or to sibutramine biodistribution. Subjects with body mass index greater than 40 Kg/m2 required a higher dose of sibutramine in order to loose the same proportion of abdominal fat as those in other types of obesity.

REFERENCES

1. Sistema Nacional de Vigilancia Epidemiológica (SNVE) de México. Ultimo informe de la OPS (1994).

2. Arroyo P, Loria A, Fernandez V, Flegal KM, Kuri-Morales P, Olaiz G, Tapia- Conyer R. Prevalence of pre-obesity and obesity in urban adult Mexicans in comparison with other large surveys. Obes Res 2000;8:179-185.

3. Filozof C, Gonzalez C, Serenday M, Mazza C, Braguinsky J. Obesity prevalence and trends in Latin-American countries. Obes Rev 2001;2:99-106.

4. Rivera JA, Barquera S, Campirano F, Campos I, Safdie M, Tovar V. Epidemiological and nutritional transition in Mexico: rapid increase of non-communicable chronic diseases and obesity. Public Health Nutr 2002;2:113-122.

5. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119:655-660.

6. Colditz GA, Willet WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, Speizer FE. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501-513.

7. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance is U.S. adults. The Third National Health and Nutrition Examinations Survey, 1988-1994. Diabetes Care 1998;21:518-24.

8. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977.

9. Fanghänel-Salmon G, Sánchez-Reyes L, Arellano-Montano S, Valdés- Liaz E, Chavira-López J, Rascón-Pacheco RA. Prevalence of risk factors for coronary disease in personnel of the General Hospital of Mexico. Salud Publica Méx 1997;39:427-432.

10. Ravussin E, Swinburn BA. Pathophysiology of obesity. Lancet 1992;340:808.

11. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. Nature 2000;404:672-677.

12. López-Alvarenga JC, Reza-Albarrán A, Zenteno-Ocampo E, Hernández P, Brito-Córdova G, González-Barranco J. Obesity degree is associated with non insulin dependent diabetes mellitus and not to hypercholesterolemia. Obes Res 1997;5:68S.

13. Fanghänel G, Sánchez-Reyes L, López-Alvarenga JC, González-Barranco J. El colesterol total tiene un comportamiento en forma de U invertida de acuerdo con el grado de obesidad y es independiente de la edad. Memorias de la XXXVIII Reunión Anual de la Sociedad Mexicana de Endocrinología y Nutrición. 1998; p. 61.

14. NHANES III. http://www.cdc.gov.libux.utmb.edu/nchs/data. Revisado el 27 de Septiembre de 2006.

15. Pérez-Navarro LM, López-Alvarenga JC, González-Barranco J. Onset of obesity in childhood has favourable influence upon adaptative changes in insulin resistance, compared with onset of obesity in adulthood. Obes Res 2000;8:105S.

16. Lira-Hernández LP, López-Alvarenga JC, Castillo-Martínez L, González- Barranco J. Onset of obesity during adulthood and not during childhood is related to DM in Mexican women. Obes Res 2000;8(suppl 1):105S.

17. Tamez-Dávila LR, López-Alvarenga JC, González-Barranco J. La edad de inicio de obesidad no es factor de riesgo para el desarrollo de enfermedades asociadas a la obesidad en obesos grado V. Memoria de la XXXVI Reunión de la Sociedad Mexicana de Endocrinología y Nutrición. 1996; p. 98.

18. Stern JS, Hirsch J, Blair SN, Foreyt JP, Frank A, Kumanyika SK, et al. Weighing the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res 1995;3:591-604.

19. National Task Force on the Prevention and Treatment of Obesity. Long-term Pharmacotherapy in the management of obesity. JAMA 1996;276:1907-1915.

20. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary. Expert Panel on the Identification, Evaluation and Treatment of Overweight in Adults. Am J Clin Nutr 1998;68:899-917.

21. Wilson PW, Kannel WB, Silbershatz H, D’Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;24:1104-1109.

22. Empana P, Ducimetiere P, Charles MA, Iouven X. Sagital abdominal diameter and risk of sudden death in asymptomatic middle-agged men: The Paris Prospective Study I. Circulation 2004;110:2781-2785.

23. Garrow JS, Summerbell CD. Meta-analysis: effect of exercise, with or without dieting, on the body composition of overweight subjects. Eur J Clin Nutr 1995; 49:1-10.

24. Andreson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001;74:579-584.

25. Borg P, Kukkonen-Harjula K, Fogelholm M, Pasanen M. Effects of walking or resistence training on weight loss maintenance in obese, middle-aged men: a randomized trial. Int J Obes 2002;26:676-683.

26. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276:1907-1915.

27. Aburto-Torres CB, López-Alvarenga JC, Bautista S, Brito-C GX, González- Barranco J, Gómez-Pérez FJ. Sexo maculino, uso de d-fenfluramina y ausencia de diabetes mellitus son factores que determinan mayor disminución de peso en pacientes obesos de la consulta externa. Estudio de casos-controles. Memorias de la XXXVI Reunión de la Sociedad Mexicana de Endocrinología y Nutrición. 1996; p. 97.

28. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 1997;21:25-29.

29. Hansen DL, Toubro S, Stock MJ, Mc Donald IA, Astrup A. Termogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-1186.

30. Astrup A. Thermogenic drugs as a strategy for treatment of obesity. Endocrine 2000;13:207-212.

31. World Health Organization. Physical Status: The use and interpretation of anthropometry. WHO Technical Report Series. Geneva: WHO; 1995, p. 329.

32. Aburto-Torres CB, López-Alvarenga JC, Cortez-Torrez E, González-Barranco J. Factores confusores asociados al análisis del cambio de peso en pacientes obesos. Memorias de la XXXVIII Reunión Anual de la Sociedad Mexicana de Endocrinología y Nutrición. 1998; p. 23.

33. Brown H, Prescott R. Applied mixed models in medicine. Chichester. John Wiley & Sons. 1999.

34. Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. Journal of Human Hypertension 2005;19:737-743.

35. Blackburn GL, Waltman BA. Pharmacotherapy to reduce visceral fat. Clinical Cornerstone 2005;7:52-60.

36. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos- Franco E, Berber A. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebocontrolled clinical trial. Clin Ther 2004; 26: 1427-1435.

37. García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio- Navarro BE, Dorantes-Alvárez LM. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel- group trial. Clin Ther 2006;28:770-782.

38. Lindmark S, Lonn L, Wiklund U, Tufvesson M, Olsson T, Eriksoson JW. Dysregulation of the autonomic nervous system can be a link between visceral adiposity and insulin resistance. Obes Res 2005;13:717-728.

39. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002;106:2459-2465.

40. Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006;79:500-508.

41. Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. A double blind randomized placebo trial of sibutramine. Obes Res 1996;4:263-270.

42. Lean ME. Sibutramine a review of clinical efficacy. Int J Obes Relat Metab Disord 1997;21:S30-S36.

43. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999:188-189.

44. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes 1998;22:32-38.

45. Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003;284: G130-G137.

46. Camilleri M. Serotonergic modulation of visceral sensation: lower gut. Gut. 2002;51(Suppl 1):i81-i86.